bluuebunny/crossref_metadata_2025_split huggingface dataset:
Use of cyanoacrylate adhesive in the surgical management of feline corneal sequestrum: 16 cases (2011‐2018)
Authors: Pumphrey Stephanie A. , Desai Sujata J. , Pizzirani Stefano 
Published: March 2019

AbstractObjectiveTo evaluate the use of cyanoacrylate adhesive as an adjunct to lamellar keratectomy in cats with corneal sequestrum.MethodsMedical records were reviewed to identify cats with naturally occurring midstromal corneal sequestra treated with lamellar keratectomy and cyanoacrylate adhesive. All cats also had a bandage contact lens placed for postoperative comfort. Data collected included breed, age, sex, and reproductive status of the cat, eye involved, presence or absence of neovascularization at the time of surgery, history of prior sequestra, additional ocular procedures performed, use of neuromuscular blocking agents, procedure time, time to cessation of topical medications, time to recurrence or last follow‐up, and complications aside from recurrence.ResultsSixteen cats met study criteria, with a median follow‐up time of 17.5 months in those without recurrence. Median time to cessation of topical medications was 4 weeks. Fourteen cats (87%) have not experienced recurrence. Other than recurrence in two cats, no significant complications were noted. Aside from purebred status, no commonalities were found between the two cats with recurrence. Neuromuscular blocking agents were not used during surgery in most cases. Median procedure time was 10 minutes.ConclusionsCyanoacrylate adhesive is an effective and safe alternative to grafting procedures in cats undergoing lamellar keratectomy for treatment of corneal sequestrum. Recurrence rates are comparable to those seen with grafting techniques. Benefits of this approach include decreased anesthesia time, lower procedure costs, and short duration of postoperative treatment.
Comparison of generic and disease‐specific measures in their ability to detect differences in pressure ulcer clinical groups
Authors: Rutherford Claudia , Campbell Rachel , Brown Julia M. , Smith Isabelle , Costa Daniel S. J. , McGinnis Elizabeth , Wilson Lyn , Gilberts Rachael , Brown Sarah , Coleman Susanne , Collier Howard , Nixon Jane E. 
Published: March 2019

ABSTRACTPatient‐reported outcomes can be included as end points in pressure ulcer (PU) intervention trials to provide information to inform decision‐making and improve the lives of patients. However, the challenge for researchers and clinicians is identifying and choosing an appropriate instrument for each particular application that suits their research questions and clinical context. To provide researchers and clinicians with the information needed to inform choice of patient‐reported outcome measures, we compared a generic and disease‐specific measures’ ability to discriminate between clinical groups known to differ, and determined their responsiveness to change. We performed analyses on a subset of patients recruited to the PRESSURE 2 trial that completed the pressure ulcer quality of life instrument—prevention version (PU‐QOL‐P) and Short Form 12 Questionnaire (SF12) measures at baseline and 30‐day posttreatment. Known‐group validity and responsiveness‐to‐change analyses were conducted. The analysis sample consisted of 617 patients that completed both measures at baseline. Known‐group validity revealed that some PU‐QOL‐P symptoms and function scales differentiated between people with category 2 PUs and those without PUs. A less meaningful pattern of results was observed for the SF12 scales, suggesting that the PU‐QOL‐P is more sensitive to differences between PU and non‐PU populations. Responsiveness analysis revealed that the PU‐QOL‐P was more responsive in detecting disease severity than the SF12. The PU‐QOL‐P provides a standardized method for assessing PU‐specific symptoms and functioning outcomes and is suitable for quantifying the benefits of PU interventions from the patient's perspective. Generic measures are useful for group comparisons of global quality of life domains. Choice of measure for each particular application should be determined by the purpose of the measurement and the information required.
Prevention and management of primary postpartum hemorrhage among puerperae in a teaching hospital in São Paulo, Brazil: a best practice implementation project
Authors: Ogawa Luciana , Shimoda Gilcéria Tochika , Wei Chang Yi , Püschel Vilanice Alves de Araújo 
Published: March 2019

ABSTRACT

Objectives:
The aim of this project was to develop and implement strategies to promote standardization and formal documentation of increased bleeding within the first 24 h after birth, in compliance with best practice.

Introduction:
Official data from Brazil shows a maternal mortality rate of around 52 to 75 deaths per 100,000 live births, 8% of which are caused by hemorrhage. Early diagnosis is promoted through standardization and formal documentation of the first signs of hemorrhage.

Methods:
The current implementation project used the Joanna Briggs Institute Practical Application of Clinical Evidence System, a baseline audit was conducted on a sample size of 108 patients and 67 nursing staff. Based on the results of the baseline audit, strategies to address non-compliance were developed and implemented. A follow-up audit was conducted on a sample size of 110 patients and 68 nursing staff, using the same audit criteria.

Results:
The baseline audit showed poor compliance with evidence-based best practice in every criterion. The implemented protocol for postpartum hemorrhage was well received by the nursing staff, promoting early diagnosis of increased bleeding within 24 h after birth and providing support for further medical treatment. There were significant improvements in every best practice criterion in the follow-up audit.

Conclusion:
The current implementation project managed to improve the nursing staff professional practice, reducing the absence of records while promoting greater awareness of the first signs of primary postpartum hemorrhage.
Contrast-enhanced carotid ultrasonography and MRI plaque imaging to identify patients developing in-stent intimal hyperplasia after carotid artery stenting
Authors: Hagiwara Yuta , Takao Naoki , Takada Tatsuro , Shimizu Takahiro , Yoshie Tomohide , Fukano Takayuki , Tokuyama Yoshiaki , Usuki Noriko , Ueda Toshihiro , Hasegawa Yasuhiro 
Published: March 2019

Aim: In-stent intimal hyperplasia (ISH) observed after carotid artery stenting (CAS) may lead to in-stent restenosis. We aimed to investigate whether contrast-enhanced carotid ultrasonography (CEUS) and magnetic resonance imaging (MRI) plaque imaging prior to CAS are predictive for ISH at 6 months after CAS.Material and method: A total of 14 patients (13 men, 1 woman; mean age, 74.2 years) were prospectively enrolled. CEUS and MRI plaque imaging were performed before CAS. ISH was diagnosed by carotid angiography at 6 months after CAS. Patients were divided into two groups based on the thicknessof ISH and age, risk factors, enhancement in CEUS, MRI plaque imaging and number of replaced stents were compared between groups.Results: Carotid angiography at 6 months after CAS revealed ISH in 10 patients. Plaque enhancement on CEUS was observed in 6 patients, all of whom showed ISH. A significant association was seen between plaque enhancement on CEUS and development of ISH (χ2 test, CEUS enhancement (+) 100% vs. CEUS enhancement (-) 50% p=0.040). Carotid plaques in 12 patients were diagnosed as unstable by MRI plaque imaging. Presence of ISH was significantly associated with unstable plaque diagnosed by MRI plaque imaging (χ2 test, unstable 83% vs. stable 0%; p=0.016).Conclusion: Carotid plaque MRI and CEUS may be useful to predict ISH after CAS.
Asymptomatic bacteriuria in pregnancy: systematic reviews of screening and treatment effectiveness and patient preferences
Authors: Wingert Aireen , Pillay Jennifer , Sebastianski Meghan , Gates Michelle , Featherstone Robin , Shave Kassi , Vandermeer Ben , Hartling Lisa 
Published: March 2019

ObjectiveTo systematically review screening and treatment effectiveness, and patient preferences, to inform recommendations by the Canadian Task Force on Preventive Health Care on screening for asymptomatic bacteriuria in pregnancy.DesignWe searched multiple databases (inception to September 2017) and grey literature sources for studies on screening effectiveness and patient preferences. For treatment with antibiotics, we searched three databases for systematic reviews and obtained search results of the Cochrane Pregnancy and Childbirth Group’s Trials Register to update a Cochrane review. Study selection, risk of bias assessment and evaluation of the quality for each outcome using Grading of Recommendations Assessment, Development and Evaluation was completed independently by two reviewers with consensus. Meta-analysis was conducted when appropriate as were analyses based on planned subgroup variables.OutcomesFor screening and treatment effectiveness: maternal and perinatal mortality, maternal and neonatal sepsis, pyelonephritis, spontaneous abortion, preterm delivery, low birth weight and serious adverse events. Valuation of outcomes for patient preferences.ResultsFour studies compared outcomes before and after the introduction of a screening programme or between different screening programmes. All evidence on screening effectiveness was considered very low quality. Women have conflicting opinions about antibiotic use during pregnancy. Fifteen trials compared antibiotic treatment with no treatment or placebo in women with confirmed bacteriuria. Low-quality evidence found that treatment lowered rates of pyelonephritis (12 trials, relative risk [RR] 0.24; 95% CI 0.13 to 0.42; absolute risk reduction [ARR] 17.6%; number needed to treat [NNT] 6, 95% CI 5 to 7) and low birth weight (seven trials, RR 0.63; 95% CI 0.45 to 0.90; ARR 4.4%; NNT 23, 95% CI 15 to 85).ConclusionsAntibiotic treatment for women having significant bacteriuria likely reduces the incidence of pyelonephritis and low birth weight, but we are uncertain about the magnitude of the effect and about the extent to which we can apply these results to asymptomatic populations and screening programmes.PROSPERO registration numberCRD42016045263.
Factors determining intention to leave among physicians in tertiary hospitals in China: a national cross-sectional study
Authors: Zhang Chunyu , Hu Linlin , Ma Jing , Wu Shichao , Guo Jing , Liu Yuanli 
Published: March 2019

ObjectiveThe reasons that physicians leave the institutions have not been extensively studied. We aimed to evaluate these reasons, which include the desire to work at another hospital or the intention to make a career change, among physicians in tertiary hospitals in China and explore the associations between the individual-level and organizational-level factors related to these two reasons for leaving.MethodsWe conducted a national survey of 136 tertiary hospitals across all 31 provinces in China between December 2017 and January 2018. A total of 20 785 physicians were selected to self-report on the two evaluated reasons related to physicians’ intent to leave. A univariate analysis and multilevel regression model were applied to evaluate the factors associated with intention to leave.ResultIn all, 10.4% of the participating physicians had thought about working at another hospital, and 20.5% intended to leave to make a career change. At the hospital level, the government subsidy per bed (OR=0.88, 95% CI: 0.86 to 0.98 and OR=0.91, 95% CI: 0.90 to 0.99), personnel funding per capita (OR=0.86, 95% CI: 0.76 to 0.96 and OR=0.80, 95% CI: 0.73 to 0.88) and the number of physicians per bed (OR=0.83, 95% CI: 0.81 to 0.86 and OR=0.89, 95% CI: 0.81 to 0.92) were negatively associated, while the number of hospital-level medical disputes (OR=1.04, 95% CI: 1.03 to 1.05 and OR=1.06, 95% CI: 1.01 to 1.11) was positively associated with both reasons for leaving. At the individual level, income (OR=0.74, 95% CI: 0.71 to 0.79 and OR=0.88, 95% CI:0.83 to 0.92) and job satisfaction (OR=0.18, 95% CI: 0.17 to 0.20 and OR=0.16, 95% CI: 0.15 to 0.18) acted as preventive factors against both reasons for leaving, while work hours per week (OR=1.11, 95% CI: 1.06 to 1.17 and OR=1.23, 95% CI: 1.19 to 1.28) and medical dispute (OR=1.49, 95% CI:1.35 to 1.65 and OR=1.77, 95% CI: 1.64 to 1.91) acted as promotive factors.ConclusionsAlthough the intention to leave is not prevalent among physicians in tertiary hospitals in China, providing more organisational support and a better occupational environment may promote retention among physicians.
Tramadol and the risk of seizure: nested case-control study of US patients with employer-sponsored health benefits
Authors: Morrow Richard L , Dormuth Colin R , Paterson Michael , Mamdani Muhammad M , Gomes Tara , Juurlink David N 
Published: March 2019

ObjectivesTramadol is a widely prescribed analgesic that influences both opioid and monoamine neurotransmission. While seizures have been reported with its use, the risk in clinical practice has not been well characterised. We examined risk of seizure with tramadol relative to codeine, a comparable opioid analgesic.DesignRetrospective nested case-control study. For each case, we identified up to 10 controls matched on age, sex, US state of residence and date of cohort entry (±365 days). We calculated ORs to determine the association between seizure and exposure to tramadol, codeine (≥15 mg), both or neither, in the preceding 30 days.SettingCohort of patients, who had continuous health coverage and resided in the same state for≥3 years, identified from linked administrative health data in US MarketScan databases from 2009 to 2012.ParticipantsWe identified 96 753 patients with seizure and 888 540 matched controls.Primary and secondary outcome measuresIn the primary analysis, we defined cases using a broad definition of seizure (based on either an outpatient physician claim for seizure disorder or a seizure-related emergency department visit or hospitalisation). In a secondary analysis, we used a more specific definition of seizure restricted to a hospital visit with a principal diagnosis of seizure.ResultsIn the primary analysis, we found no association between risk of seizure and exposure to tramadol compared with codeine (OR 1.03, 95% CI 0.93 to 1.15). However, in the secondary analysis (using a more specific definition of seizure), this association was statistically significant (OR 1.41, 95% CI 1.11 to 1.79).ConclusionsTramadol was not associated with an increased risk of seizure defined by inpatient and outpatient diagnoses. However, this finding was sensitive to the outcome definition used and requires further study.
Cardiovascular risk in 159 934 frequent blood donors while addressing the healthy donor effect
Authors: Peffer Karlijn , den Heijer Martin , de Kort Wim L A M , Verbeek André L M , Atsma Femke 
Published: March 2019

ObjectiveTo investigate whether regular blood donation decreases cardiovascular risk.MethodsAll 159 934 Dutch whole-blood donors with an active donation career of at least 10 years were categorised into sex-specific donation tertiles based on the number of donations during this 10-year qualification period. Cardiovascular endpoints were based on hospital discharge diagnoses and death certificates from Dutch Hospital Data and Statistics Netherlands and occurring after the 10-year qualification period. Cox regression was used to estimate the age-adjusted and starting year-adjusted hazard rate ratio (HRR).ResultsFemale high-frequency blood donors had a reduced cardiovascular morbidity (HRR=0.91, 95% CI 0.85 to 0.98) compared with low-frequency blood donors. No effect was observed in men (HRR=1.00, 95% CI 0.95 to 1.05). To rule out a residual healthy donor effect (HDE), additional sensitivity analyses using a 5-year qualification period were conducted. The results supported the absence of a residual HDE.ConclusionsThis study showed a protective effect of long-term, high-frequency blood donation against cardiovascular disease. This effect was only observed in women and not in men.
Outcome-Oriented Predictive Process Monitoring
Authors: Teinemaa Irene , Dumas Marlon , Rosa Marcello La , Maggi Fabrizio Maria 
Published: March 2019

Predictive business process monitoring refers to the act of making predictions about the future state of ongoing cases of a business process, based on their incomplete execution traces and logs of historical (completed) traces. Motivated by the increasingly pervasive availability of fine-grained event data about business process executions, the problem of predictive process monitoring has received substantial attention in the past years. In particular, a considerable number of methods have been put forward to address the problem of outcome-oriented predictive process monitoring, which refers to classifying each ongoing case of a process according to a given set of possible categorical outcomes—e.g., Will the customer complain or not? Will an order be delivered, canceled, or withdrawn? Unfortunately, different authors have used different datasets, experimental settings, evaluation measures, and baselines to assess their proposals, resulting in poor comparability and an unclear picture of the relative merits and applicability of different methods. To address this gap, this article presents a systematic review and taxonomy of outcome-oriented predictive process monitoring methods, and a comparative experimental evaluation of eleven representative methods using a benchmark covering 24 predictive process monitoring tasks based on nine real-life event logs.
Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma
Authors: Floc'h Nicolas , Ashton Susan , Ferguson Douglas , Taylor Paula , Carnevalli Larissa S. , Hughes Adina M. , Harris Emily , Hattersley Maureen , Wen Shenghua , Curtis Nicola J. , Pilling James E. , Young Lucy A. , Maratea Kim , Pease Elizabeth J. , Barry Simon T. 
Published: March 2019

Abstract
Barasertib (AZD1152), a pro-drug of the highly potent and selective Aurora B kinase inhibitor AZD2811, showed promising clinical activity in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients administered as a 4-day infusion. To improve potential therapeutic benefit of Aurora B kinase inhibition, a nanoparticle formulation of AZD2811 has been developed to address limitations of repeated intravenous infusion. One of the challenges with the use of nanoparticles for chronic treatment of tumors is optimizing dose and schedule required to enable repeat administration to sustain tumor growth inhibition. AZD2811 gives potent cell growth inhibition across a range of DLBCL cells lines in vitro. In vivo, repeat administration of the AZD2811 nanoparticle gave antitumor activity at half the dose intensity of AZD1152. Compared with AZD1152, a single dose of AZD2811 nanoparticle gave less reduction in pHH3, but increased apoptosis and reduction of cells in G1 and G2–M, albeit at later time points, suggesting that duration and depth of target inhibition influence the nature of the tumor cell response to drug. Further exploration of the influence of dose and schedule on efficacy revealed that AZD2811 nanoparticle can be used flexibly with repeat administration of 25 mg/kg administered up to 7 days apart being sufficient to maintain equivalent tumor control. Timing of repeat administration could be varied with 50 mg/kg every 2 weeks controlling tumor control as effectively as 25 mg/kg every week. AZD2811 nanoparticle can be administered with very different doses and schedules to inhibit DLBCL tumor growth, although maximal tumor growth inhibition was achieved with the highest dose intensities.
Decreased miR-218–5p Levels as a Serum Biomarker in Bone Metastasis of Prostate Cancer
Authors: Peng Peng , Chen Tao , Wang Qing , Zhang Yixi , Zheng Fangfang , Huang Shuai , Tang Yubo , Yang Chunxiao , Ding Wenqing , Ren Dong , Huang Zongwen , Guo Yuanqing 
Published: March 2019

<b><i>Background:</i></b> miR-218–5p is an extensively studied microRNA (miRNA) in prostate cancer (PCa). However, the clinical significance and biological role of miR-218–5p in bone metastasis of PCa remain unclear. <b><i>Materials and Methods:</i></b> miR-218–5p expression was evaluated in 38 bone metastatic and 115 non-bone metastatic PCa tissues and serum samples. Clinical correlation of miR-218–5p expression with clinicopathological characteristics was analyzed. The biological roles of miR-218–5p in bone metastasis of PCa were investigated in vitro by invasion and migration assays. Bioinformatics analysis, real-time polymerase chain reaction, western blot, and luciferase reporter assay were applied to discern and examine the relationship between miR-218–5p and its potential targets. <b><i>Results:</i></b> miR-218–5p expression was reduced in bone metastatic PCa tissue and serum samples, which positively correlated with poor clinicopathological characteristics and bone metastasis-free survival in PCa patients. Upregulating miR-218–5p repressed PCa cell invasion and migration. Furthermore, miR-218–5p inhibited NF-κB signaling via simultaneously targeting TRAF1, TRAF2, and TRAF5, which suppressed the invasion and migration abilities of PCa cells. ROC curve analysis of miR-218–5p in the serum of PCa patients exhibited an area under the curve of 0.86 (95% confidence interval 0.80–0.92, p &#x3c; 0.001). <b><i>Conclusion:</i></b> Our findings indicate that miR-218–5p might represent a novel serum biomarker for bone metastasis of PCa.
Smoking and Increased White and Red Blood Cells
Authors: Pedersen Kasper Mønsted , Çolak Yunus , Ellervik Christina , Hasselbalch Hans Carl , Bojesen Stig Egil , Nordestgaard Børge Grønne 
Published: March 2019

Objective—
Whether tobacco smoking causally affects white and red blood cells and thrombocyte counts is unknown. Using a Mendelian randomization approach, we tested the hypothesis that smoking causes increases in these blood cell indices.

Approach and Results—

We included 104 607 white Danes aged 20 to 100 years from the Copenhagen General Population Study with information on blood cell indices, smoking habits, and
CHRNA3
(alpha 3 nicotinic cholinergic receptor) rs1051730 genotype, where the T allele causes higher tobacco consumption; 41 759 were former smokers and 17 852 current smokers. In multivariable adjusted observational analyses and compared with never smokers, white blood cells were associated with up to 19% increases, thrombocytes with up to 4.7% increases, and red blood cell indices with up to 2.3% increases in former and current smokers. All associations were dose dependent, with tobacco consumption but for white blood cells and thrombocytes also dependent on smoking cessation time in former smokers; highest increases were for <1-year smoking cessation and lowest increases for >10-year smoking cessation. In age- and sex-adjusted genetic analyses, percent differences per T allele increase in current smokers were 1.15% (95% CI, 0.61%–1.68%) for leukocytes, 1.07% (0.38%–1.76%) for neutrophils, 1.34% (0.66%–2.02%) for lymphocytes, 1.50% (0.83%–2.18%) for monocytes, −0.60% (−1.91% to 0.74%) for eosinophils, 0.17% (−0.94% to 1.29%) for basophils, 0.38% (−0.17% to 0.93%) for thrombocytes, 0.04% (−0.14% to 0.23%) for erythrocytes, 0.34% (0.17% to 0.50%) for hematocrit, 0.26% (0.09% to 0.43%) for hemoglobin, and 0.29% (0.18% to 0.41%) for mean corpuscular volume.

Conclusions—
Smoking causes increased blood leukocytes, neutrophils, lymphocytes, and monocytes, as well as increased hematocrit, hemoglobin, and mean corpuscular volume. The observational smoking relationships were long term for white blood cells and short term for red blood cell indices.